Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis

Eastern Mediterranean Health Journal

Volumn 9, Issue 4, 2003, Pages 518-533

  Croft, S L ^a   Vivas, L ^a   Brooker, S ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ATOVAQUONE PLUS PROGUANIL; CIRCUMSPOROZOITE PROTEIN; DIHYDROARTEMISININ; DNA VACCINE; FANSIDAR; GLUTAMATE RICH PROTEIN; INSECTICIDE; MALARIA VACCINE; MEFLOQUINE; MEGLUMINE ANTIMONATE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PYRIMETHAMINE; RECOMBINANT ERYTHROCYTE MEMBRANE PROTEIN 1; SITAMAQUINE; STIBOGLUCONATE SODIUM; SULFADOXINE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCL 2510;

AFRICA; AFRICA SOUTH OF THE SAHARA; AGRICULTURE; BED NET; CHEMOTHERAPY; CIVIL DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; ENVIRONMENTAL FACTOR; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; INFECTION RISK; LEISHMANIA INFANTUM; LEISHMANIASIS; MALARIA; MEDICAL RESEARCH; NONHUMAN; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHOOL HEALTH SERVICE; SIDE EFFECT; SOUTHERN EUROPE; SUPERINFECTION; TRYPANOSOMIASIS; URBANIZATION; VACCINATION; VECTOR CONTROL; WORLD HEALTH ORGANIZATION;

ANIMALS; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; DISEASE VECTORS; HUMANS; LEISHMANIASIS; MALARIA; MEDITERRANEAN REGION; PEST CONTROL; PUBLIC HEALTH; RESEARCH; RISK FACTORS; SCHISTOSOMIASIS; TRYPANOSOMIASIS, AFRICAN; VACCINATION; WORLD HEALTH;

EID: 16844377897     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. The world health report 2003 - shaping the future. Geneva, World Health Organization, 2003 (http://www.who.int/whr/2003/en/, accessed 23 June 2004).
2. Strategic direction for research. Geneva, Special Programme for Research and Training in Tropical Diseases, 2002 (http://www.who.int/tdr/diseases/malaria/direction.htm, accessed 23 June 2004.
3. Sachs JD. A new global effort to control malaria. Science 2002, 298(5591): 122-4.
4. Greenwood B et al. Malaria in 2002. Nature, 2002, 415(6872):670-2.
5. Goodman CA et al. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet, 1999, 354(9176):378-85.
6. Murray CK et al. Rapid diagnostic testing for malaria. Tropical medicine and international health, 2003, 8(10):876-83.
7. Gascoyne P et al. Microfluidic approaches to malaria detection. Acta tropica, 2004, 89(3):357-69.
8. Piper R et al. Immunocapture diagnostic assays for malaria using plasmodium lactate dehydrogenase (pLDH). American journal of tropical medicine and hygiene, 1999, 60(1):109-18.
9. Moreno A et al. Use of the DELI-microtest to determine the drug sensitivity of Plasmodium falciparum in Burkina Faso. Annals of tropical medicine and parasitology, 2001, 95(3):309-12.
10. Moody A. Rapid diagnostic tests for malaria parasites. Clinical microbiology reviews, 2002, 15(1):66-78.
11. Palmer CJ et al. Multicenter study to evaluate the OptiMAL test for rapid diagnosis of malaria in U.S. hospitals. Journal of clinical microbiology, 2003, 41(11):5178-82.
12. Huong NM et al. Comparison of three antigen detection methods for diagnosis and therapeutic monitoring of malaria: a field study from southern Vietnam. Tropical medicine and international health, 2002, 7(4):304-8.
13. Forney JR et al. Devices for rapid diagnosis of Malaria: evaluation of prototype assays that detect Plasmodium falciparum histidine-rich protein 2 and a Plasmodium vivax-specific antigen. Journal of clinical microbiology, 2003, 41(6): 2358-66.
14. Wongsrichanalai C et al. Rapid diagnostic devices for malaria: field evaluation of a new prototype immunochromatographic assay for the detection of Plasmodium falciparum and non-falciparum Plasmodium. American journal of tropical medicine and hygiene, 2003, 69(1): 26-30.
15. Toure YT et al. The challenges of doing more against malaria, particularly in Africa. Bulletin of the World Health Organization, 2000, 78(12):1376.
16. Maxwell CA et al. Variation of malaria transmission and morbidity with altitude in Tanzania and with introduction of alphacypermethrin treated nets. Malaria journal, 2003, 2(1):28.
17. Howard N et al. Socio-economic factors associated with the purchasing of insecticide-treated nets in Afghanistan and their implications for social marketing. Tropical medicine and international health, 2003, 8(12):1043-50.
18. Guyatt HL et al. Too poor to pay: charging for insecticide-treated bednets in highland Kenya. Tropical medicine and international health, 2002, 7(10):846-50.
19. Onwujekwe O et al. Inequalities in purchase of mosquito nets and willingness to pay for insecticide-treated nets in Nigeria: challenges for malaria control interventions. Malaria journal, 2004, 3(1):6.
20. Africa malaria report 2003. Geneva, United Nations Children's Fund and the World Health Organization, 2003 (http://www.rbm.who.int/amd2003/amr2003/amr_toc.htm, accessed 23 June 2004).
21. Bhatia MR et al. Cost-effectiveness of malaria control interventions when malaria mortality is low: insecticide-treated nets versus in-house residual spraying in India. Social science and medicine, 2004, 59(3):525-39.
22. Guerin PJ et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet infectious diseases, 2002, 2(9):564-73.
23. Hoffman SL et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Journal of infectious diseases, 2002, 185(8):1155-64.
24. Luke TC et al. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. Journal of experimental biology, 2003, 206(Pt 21):3803-8.
25. Butler D. Mosquito production mooted as fast track to malaria vaccine. Nature, 2003, 425(6957):437.
26. Bojang KA et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet, 2001, 358(9297):1927-34.
27. Moorthy VS, Good HF, Hill AV. Malaria vaccine developments. Lancet, 2004, 363(9403):150-6.
28. Epstein JE et al. Safety, tolerability and antibody response in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine, 2004, 22(13-14):1592-603.
29. Attaran A et al. WHO, the Global Fund, and medical malpratice in malaria treatment. Lancet, 2004, 363(9404):237-40.
30. McGready R et al. Artemisinin anti-malarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clinical infectious dieseases, 2001, 33(12):2009-16.
31. Nosten F et al. Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a nonepidemic year. Journal of infectious diseases, 2003, 188(8):1259-61; author reply 1561-2.
32. Schellenberg D et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet, 2001, 357(9267): 1471-7.
33. Trouiller P et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet, 2002, 359(9324):2188-94.
34. MMV pojects. Geneva, Medicines for Malaria Venture, 2003 fs(http://www.mmv.org/pages/ content_frame.asp?ThePage=page1_0003_1.htm&Nav=0003, accessed 26 June 2004).
35. Nwaka S et al. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature review. Drug discovery, 2003, 2(11):919-28.
36. Leishmaniasis. Geneva, Special Programme for Research and Training in Tropical Diseases, 2002 (http://www.who.int/tdr/diseases/leish/diseaseinfo.htm, accessed 23 June 2004).
37. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95(3):239-43.
38. Berhe N et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS, 1999, 13(14):1921-5.
39. Cruz I et al. Leishmania in discarded syringes from intravenous drug users. Lancet, 2002, 359(9312):1124-5.
40. Herwaldt BL. Leishmaniasis. Lancet, 1999, 354(9185):1191-9.
41. Guerin PJ et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet infectious diseases, 2002, 2(8):494-501.
42. Boelaert M et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. American journal of tropical medicine and hygiene, 2004, 70(1):72-7.
43. Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical medicine and international health, 2001, 6(11): 849-54.
44. Lira R et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. Journal of infectious diseases, 1999, 180(2):564-7.
45. Thakur CP et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93(3):319-23.
46. Sundar S et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clinical infectious diseases, 2003, 37(6):800-4.
47. Sundar S et al. Oral miltefosine for Indian visceral leishmaniais. New England journal of medicine, 2002, 347(22): 1739-46.
48. Thakur CP et al. A prospective randomised, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94(4):429-31.
49. De La Rosa R et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. Journal of clinical microbiology, 2002, 40(3):762-7.
50. Garnier T et al. Topical treatment for cutaneous leishmaniasis. Current opinion in investigational drugs, 2002, 3(4):538-44.
51. Asilian A et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bulletin of the World Health Organization 2003, 81(5):353-9.
52. Arevalo I et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clinical infectious diseases, 2001, 33(11):1847-51.
53. Brodskyn C et al. Vaccines in leishmaniasis: advances in the last five years. Expert review of vaccines, 2003, 2(5): 705-17.
54. Gavgani AS et al. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet, 2002, 360(9330): 374-9.
55. Stich A et al. Human African trypanosomiasis. British medical journal, 2002, 325(7357):203-6.
56. Barrett MP et al. The trypanosomiases. Lancet, 2003, 362(9394):1469-80.
57. Fevre EM et al. The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda. Lancet 2001 358(9282):625-8.
58. Simarro PP et al. Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis ( T.b. gambiense) focus of Quicama (Angola). Tropical medicine and international health, 1999, 4(12): 858-61.
59. Papadopoulos MC et al. A novel and accurate diagnostic test for human African trypanosomiasis. Lancet, 2004, 363 (9418):1358-63.
60. Barry JD et al. Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite. Advances in parasitology, 2001, 49:1-70.
61. Legros D et al. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet infectious diseases, 2002, 2(7):437-40.
62. Burri C et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet, 2000, 355(9213):1419-25.
63. Pepin J et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bulletin of the World Health Organization, 2000, 78(11):1284-95.
64. Grant IF. Insecticides for tsetse and trypanosomiasis control: is the environmental risk acceptable? Trends in parasitology 2001, 17(1):10-4.
65. Awasthi S et al. Helminthic infections. British medical journal, 2003, 327 (7412):431-3.
66. Jukes MC et al. Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Tropical medicine and international health, 2002, 7(2):104-17.
67. McGarvey ST et al. Child growth, nutritional status, and schistosomiasis japonica in Jiangxi, People's Republic of China. American journal of tropical medicine and hygiene, 1993, 48(4): 547-53.
68. Hatz CF. The use of ultrasound in schistomiasis. Advances in parasitology, 2001, 48:225-84.
69. Boisier P et al. Reversibility of Schistosoma mansoni associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92(4): 451-3.
70. Frenzel K et al. Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda. American journal of tropical medicine and hygiene, 1999, 60(6):927-31.
71. Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta tropica, 2003, 86(2-3):161-83.
72. McGarvey ST et al. Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, the Phippines: a randomized trial of praziquantel versus placebo. American journal of tropical medicine and hygiene, 1996, 54(5):498-502.
73. Nokes C et al. Evidence for an improvement in cognitive function following treatment of Schistosoma japonicum infection in Chinese primary schoolchildren. American journal of tropical medicine and hygiene, 1999, 60(4): 556-65.
74. Savioli L et al. Schistosomiasis and soil-transmitted helminth infections: forging control efforts. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96(6):577-9.
75. Hall A et al. Alternatives to bodyweight for estimating the dose of praziquantel needed to treat schistosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93(6): 653-8.
76. Montresor A et al. Development and validation of a 'tablet' pole for the administration of praziquantel in sub-Saharan Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95(5):542-4.
77. Lengeler C et al. Screening for schistosomiasis with questionnaires. Trends in parasitology, 2002, 18(9):375-7.
78. Schistosomiasis control initiative. London, Department of Infectious Disease Epidemiology, Imperial College London, 2004 (http://www.schisto.org, accessed 28 June 2004).
79. Hamilton JV et al. Diagnosis of schistosomiasis: antibody detection, with notes on parasitological and antigen detection methods. Parasitology, 1998, 117 (suppl.):S41-57.
80. Doenhoff MJ et al. Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies? Trends in parasitology, 2004, 20(1):35-9.
81. Pontes LA et al. Detection by polymerase chain reaction of Schistosoma mansoni DNA in human serum and feces. American journal of tropical medicine and hygiene, 2002, 66(2):157-62.
82. Fenwick A et al. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends in parasitology, 2003, 19(11):509-15.
83. Utzinger J et al. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert opinions in pharmacotherapy, 2004, 5(2):263-85.
84. Albonico M. Methods to sustain drug efficacy in helminth control programmes. Acta tropica, 2003, 86(2-3):233-42.
85. Danso-Appiah A et al. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends in parasitology, 2002, 18(3):125-9.
86. Hagan P et al. Schistosomiasis control: keep taking the tablets. Trends in parasitology, 2004, 20(2):92-7.
87. Utzinger J et al. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Current medicinal chemistry, 2001, 8(15):1841-60.
88. Utzinger J et al. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet 2000, 355(9212):1320-5.
89. El Baz MA et al. Clinical and parasitological studies on the efficacy of Mirazid in treatment of schistosomiasis haematobium in Tatoon, Etsa Center, El Fayoum Governorate. Journal of the Egyptian Society of Parasitology, 2003, 33(3):761-76.
90. Coulson PS. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Advances in parasitology, 1997, 39: 271-336.
91. Wynn TA et al. Defining a schistosomiasis vaccination strategy - is it really Th1 versus Th2? Parasitology today, 2000, 16(11):497-501.
92. Hagan P et al. Schistosomiasis vaccines. Expert opinion on biological therapy, 2003, 3(8):1271-8.
93. Pearce EJ. Progress towards a vaccine for schistosomiasis. Acta tropica, 2003, 86(2-3):309-13.
94. Mountford AP et al. Interleukin-12 and protective immunity to schistosomes. Brazilian journal of medical and biological research, 1998, 31(1):163-9.
95. Wilson RA et al. Strategies for a schistosome vaccine: can we manipulate the immune response effectively? Microbes and infection, 1999, 1(7):535-43.
96. Da'Dara AA et al. A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection. Parasite immunology, 2003, 25(8-9):429-37.
97. The Schistosoma mansoni Genome Project. Hinxton, Cambridge, United Kingdom, The Wellcome Trust Sanger Institute, 2003 (http://www.sanger.ac.uk/Projects/S_mansoni/, accessed 28 June 2004).
98. Utzinger J et al. Sustainable schistosomiasis control - the way forward. Lancet, 2003, 362(9399):1932-4.